IP Library Granted Patent US 11,162,114
Granted Patent B2
US 11,162,114 · App. 16/432,321 · Granted Nov 2, 2021

RNA-guided nucleases and active fragments and variants thereof and methods of use

Inventors: Alexandra Briner Crawley (Cary, NC); Rodolphe Barrangou (Raleigh, NC); Tyson D. Bowen (Morrisville, NC); Michael Coyle (Chapel Hill, NC); Tedd D. Elich (Durham, NC)
Assignee: LifeEDIT Therapeutics, Inc.
C12N15/907C12N9/22C12N15/11C12N15/902C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,162,114
App. No.
16/432,321
Granted
Nov 2, 2021
Kind
B2
Abstract

Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.

Claims (39)

1. A nucleic acid molecule comprising a polynucleotide encoding an RNA-guided nuclease (RGN) polypeptide, wherein said polynucleotide comprises a nucleotide sequence encoding an RGN polypeptide comprising an amino acid sequence:

(i) having at least 95% sequence identity to SEQ ID NOs: 11, 27, 45 or 54;

(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or

(iii) set forth in SEQ ID NO: 36;

wherein said RGN polypeptide binds a target DNA sequence in an RNA-guided sequence specific manner when bound to a guide RNA (gRNA) capable of hybridizing to said target DNA sequence, and

wherein said polynucleotide encoding an RGN polypeptide is operably linked to a promoter heterologous to said polynucleotide.

2. The nucleic acid molecule of claim 1 , wherein said RGN polypeptide is nuclease dead or functions as a nickase.

3. The nucleic acid molecule of claim 2 , wherein the RGN polypeptide is operably fused to a base-editing polypeptide.

4. A vector comprising the nucleic acid molecule of claim 1 .

5. The vector of claim 4 , wherein said vector further comprises at least one nucleotide sequence encoding said guide RNA, and wherein the guide RNA comprises a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NOs: 2, 12, 20, 28, 37, 46, or 55.

6. The vector of claim 4 , wherein the guide RNA comprises a tracrRNA having at least 95% sequence identity to SEQ ID NOs: 3, 13, 21, 29, 38, 47, or 56.

7. A cell comprising the nucleic acid molecule of claim 1 .

8. A system for binding a target DNA sequence, said system comprising:

a) one or more guide RNAs capable of hybridizing to said target DNA sequence or one or more nucleotide sequences encoding the one or more guide RNAs (gRNAs); and

b) an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence:

(i) having at least 95% sequence identity to SEQ ID NOs: 11, 27, 45 or 54;

(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19;

(iii) set forth in SEQ ID NO: 36; or

a nucleotide sequence encoding the RGN polypeptide;

wherein said nucleotide sequences encoding the one or more guide RNAs and encoding the RGN polypeptide are each operably linked to a promoter heterologous to each said nucleotide sequence;

wherein the one or more guide RNAs hybridize to the target DNA sequence, and

wherein the one or more guide RNAs form a complex with the RGN polypeptide, thereby directing said RGN polypeptide to bind to said target DNA sequence.

9. The system of claim 8 , wherein the target DNA sequence is within a eukaryotic cell.

10. The system of claim 8 , wherein said RGN polypeptide is nuclease dead or functions as a nickase, and wherein the RGN polypeptide is operably linked to a base-editing polypeptide.

11. The system of claim 8 , wherein said system further comprises one or more donor polynucleotides or one or more nucleotide sequences encoding the one or more donor polynucleotides, wherein said nucleotide sequences encoding the one or more donor polynucleotides are each operably linked to a promoter heterologous to each said nucleotide sequence.

12. A method for binding a target DNA sequence comprising delivering the system according to claim 8 , to said target DNA sequence or a cell comprising the target DNA sequence.

13. A method for cleaving and/or modifying a target DNA sequence, comprising contacting the target DNA sequence with:

a) an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence:

(i) having at least 95% sequence identity to SEQ ID NOs: 11, 27, 45 or 54;

(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or

(iii) set forth in SEQ ID NO: 36; and

b) one or more guide RNAs capable of targeting the RGN of (a) to the target DNA sequence;

wherein the one or more guide RNAs hybridize to the target DNA sequence, thereby directing said RGN polypeptide to bind to said target DNA sequence and cleavage and/or modification of said target DNA sequence occurs.

14. The method of claim 13 , wherein said modified target DNA sequence comprises insertion of heterologous DNA into the target DNA sequence.

15. The method of claim 13 , wherein said modified target DNA sequence comprises deletion of at least one nucleotide from the target DNA sequence.

16. The method of claim 13 , wherein said modified target DNA sequence comprises mutation of at least one nucleotide in the target DNA sequence.

17. The method of claim 14 , wherein the target DNA sequence is within a cell.

18. The method of claim 17 , wherein the cell is a eukaryotic cell.

19. The method of claim 17 , further comprising culturing the cell under conditions in which the RGN polypeptide is expressed and cleaves the target DNA sequence to produce a modified DNA sequence; and selecting a cell comprising said modified DNA sequence.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: AGBIOME, INC.
To: LIFEEDIT THERAPEUTICS, INC.
Reel/Frame 057488/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: LIFEEDIT, LLC
To: AGBIOME, LLC
Reel/Frame 057488/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: AGBIOME, LLC
To: AGBIOME, INC.
Reel/Frame 057488/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: LIFEEDIT, INC.
To: LIFEEDIT, LLC
Reel/Frame 057487/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: NORTH CAROLINA STATE UNIVERSITY
To: LIFEEDIT, INC.
Reel/Frame 053343/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: BOWEN, TYSON D.; ELICH, TEDD D.; COYLE, MICHAEL
To: LIFEEDIT, INC.
Reel/Frame 053219/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: CRAWLEY, ALEXANDRA BRINER; BARRANGOU, RODOLPHE
To: NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 053219/0534 →
Continuity (10)
Provisional Application 62680845 · Jun 5, 2018
Provisional Application 62680846 · Jun 5, 2018
Provisional Application 62680853 · Jun 5, 2018
Provisional Application 62680859 · Jun 5, 2018
Provisional Application 62680862 · Jun 5, 2018
Provisional Application 62680863 · Jun 5, 2018
Provisional Application 62686901 · Jun 19, 2018
Provisional Application 62805041 · Feb 13, 2019
Provisional Application 62805045 · Feb 13, 2019
Related Publication 20190367949A1 · Dec 5, 2019
Cited By (3)
US 12,390,538 US 12,558,437 US 12,680,096